Alzheimer's screening and therapies
Home · Brain, mental health, sleep and senses · Calendar
Tags: Screening and earlier detection · Drugs and biologics
Current state
Banner has announced the first randomization in API-2, testing donanemab, nivagacetor and their combination in the Colombian PSEN1 E280A kindred. The registered primary endpoints concern amyloid removal/maintenance, so this is no demonstration of dementia prevention. It joins a broader pipeline in which biomarker and diagnostic-management findings must remain distinct from cognitive/function outcomes. The prior PLASMAR disclosure study did not test treatment efficacy, and presymptomatic combinations remain investigational.
Status: active. Initial baseline checked 2026-09-12; selective watchlist, not a systematic review.
Questions to follow
- New screening or diagnostic tests, including blood-based approaches, and formal human studies of prevention and treatment.
- Distinguish population screening of asymptomatic people from diagnostic testing of people with cognitive symptoms, specialist confirmation, and trial-enrollment tests.
- For tests, track independent prospective validation, sensitivity, specificity, predictive values in the intended population, reference standards, downstream testing, clinical utility, and U.S. authorization.
- For therapies, prioritize cognition, daily function, quality of life, and clinically meaningful progression alongside biomarker effects.
- Follow safety, including relevant imaging abnormalities or hemorrhage for therapies where applicable; identify trial population, eligibility, monitoring requirements, and treatment burden.
- Include new mechanisms and prevention trials, not just updates to existing treatment classes.
Programs and next milestones
Focused update — 2026-10-16
Colombian Alzheimer prevention study announces its first randomization
Development stage: Banner Health announced October 15 that the first participant had been randomly assigned in API-2 (NCT06996730). The phase 2/3 study plans 240 participants from the Colombian PSEN1 E280A kindred: 200 mutation carriers and 40 noncarriers. In Part 1, carriers receive donanemab to remove amyloid. Part 2 compares donanemab, oral nivagacetor (RG6289), both, or placebo after sufficient plaque clearance. Noncarriers receive placebo separately rather than entering the carrier randomization.
Evidence and limitations: This is an initiation milestone, not a prevention result. The registry's primary outcomes are PET-measured amyloid reduction and maintenance of low amyloid levels; the public registered outcome list does not establish a powered dementia-onset endpoint. Rare autosomal-dominant disease is distinct from common late-onset Alzheimer disease. The announcement does not provide the exact randomization date or new safety data.
U.S. status: Donanemab has an early-symptomatic Alzheimer indication, but presymptomatic treatment and this combination remain investigational. Nivagacetor is investigational.
Next milestone: Live registry lists recruiting, actual study start July 8, 2026, and estimated primary/final completion June 1, 2030. Its September 2 record predates the first-randomization announcement; study start is not the same event as randomization.
Remaining gaps: Focused prevention/development update, with saved registries and all 38 discovery records retrieved. Added the investigator-announced first randomization in API-2, whose live registry was fetched separately. Previously saved PLASMAR, AHEAD, ultrasound/vaccine and SPINOZA entries were deduplicated. The October 8 Neurology Clinical Practice correction/replacement of a donanemab meaningfulness analysis was located by its journal index, but the correction text could not be retrieved; do not infer its substance. Full anti-amyloid label/ARIA/recall inventories, assay comparative utility and paid interviews remain incomplete. No full successful-check advancement.
Informal-source coverage: Indexed original October 10 Reddit/NYT discussion and Attia–Davidson public episode material were checked as leads. Neither provides new randomized confirmation of obicetrapib dementia prevention. SPINOZA remains a biomarker-focused registered program; the saved clinical-prevention hypothesis stays unconfirmed. Full paid transcript and podcast census remain incomplete.
Focused update — 2026-10-13
PLASMAR finds earlier blood-test disclosure changes memory-clinic decisions
Publication: October 5, 2026; recovered October 13. PLASMAR/NCT06246019 randomized 220 new patients with subjective cognitive decline, MCI or mild dementia at one Spanish memory clinic to p-tau217/NfL disclosure at three versus nine months, alongside usual assessment.
At three months, clinician confidence of at least 90% in the etiologic diagnosis occurred in 56/112 (50.0%) versus 5/108 (4.6%), p<.001. Symptomatic-treatment initiation was 16/112 versus 5/108, difference 9.7 percentage points (95% CI 1.8–17.8). Diagnostic confidence generally converged after later disclosure; follow-up/discharge measures included clinician-reported plans.
Limits/harms: Confidence is not independently confirmed diagnostic accuracy. The trial did not establish improved cognition, function, quality of life or disease course. No significant worsening in emotional outcomes was found. Available paired questionnaires varied by instrument; HADS included 211 at baseline, 135 for baseline-to-three-month change and 94 for three-to-nine-month change. Open disclosure, one center and underpowered subgroup analyses constrain interpretation.
U.S./next: No new U.S. authorization or healthy-population screening recommendation. Multicenter diagnostic pathways, downstream outcomes and access need study; no announced next date.
Sources: Source 1.
AHEAD screening analysis finds differences in p-tau217 distributions
Publication: October 12, 2026. A cross-sectional analysis of 15,612 AHEAD 3-45 screening participants, aged 55–80 at 106 sites in four world regions, uses samples collected July 2020–October 2024 before medical/cognitive exclusions.
Plasma %p-tau217 levels were lower in self-identified Asian, Black and Hispanic groups than White/non-Hispanic groups; APOE ε4 was associated with higher levels throughout. The APOE–biomarker association varied by race/ethnicity. Associations between %p-tau217 and amyloid PET had no significant pairwise racial differences, but ethnicity-related differences were found.
Limits: This is a selected trial-screening cohort and association analysis, not a randomized screening strategy, a causal biological explanation by race, or demonstration of unequal sensitivity/specificity. Self-reported social categories, APOE, pathology prevalence and other context require careful interpretation. The primary abstract was appraised; full tables and supplements remain a gap. Do not transpose %p-tau217 findings to every assay or claim an improved health outcome.
U.S./next: No new asymptomatic-population authorization or cutoff recommendation. External calibration and prospective screening-pathway outcomes are needed; timing unannounced.
NMS-01 registers an early focused-ultrasound Alzheimer safety study
Source: First posted October 9, 2026; actual study start January 5, 2026. Neumous NMS-01/NCT07869238 is a recruiting, single-center open-label focused-ultrasound pilot in ten planned patients with mild/moderate Alzheimer disease.
Primary measures are successful/accurate transient blood-brain barrier opening, its recovery by 24 hours or seven days, and adverse events through day seven. It is a device study with no assigned drug phase.
Limits/safety/U.S.: No comparator or results. Opening the barrier is a technical endpoint, not demonstrated cognitive benefit or long-term safety. Registry access is not U.S. marketing approval. Do not infer benefit from the technology's proposed delivery mechanism.
Next: October 31, 2026 primary and November 30, 2026 final completion estimates. An elapsed/future estimate does not establish completed follow-up or available results.
Sources: Source 1.
Remaining gaps: Read full active scope, prior gaps/state and September 5 overlap. Retrieved all 14 named registries and 35 new-registration matches. Appraised PLASMAR full randomized clinical-utility article and Oct 12 AHEAD primary abstract; NMS-01 device record separately appraised.; AHEAD full tables/supplement not available. All antibody labels/ARIA changes, blood-assay recalls, worldwide prevention cohorts and clinical-outcome inventory remain incomplete. Registry October 13 refreshes do not by themselves mean new efficacy or actual first dosing.
Informal-source coverage: Revisited Attia/Davidson public original source and SPINOZA live registry; cognitive-prevention hypothesis remains unconfirmed. October 10 Reddit semaglutide-prevention headline appears to repeat older observational associations and is not a new randomized benefit. Patient-care anecdotes and stock discussions not promoted. Full paid interview and broad podcast review remain incomplete.
Focused update — 2026-10-09
Baseline recovered: TREMHANCE is recruiting for oral SAR448851
Baseline, not new October news. First posted July 7, 2026; latest posted update September 22. The registry now verifies TREMHANCE/NCT07688213, Sanofi's phase 2 oral SAR448851 study, as recruiting, with actual start July 28, 2026.
The double-blind placebo-controlled portion plans up to 160 adults with amyloid-confirmed MCI due to Alzheimer disease or mild Alzheimer dementia. Treatment lasts 48 weeks, followed by an open-label extension. The primary efficacy endpoint is plasma p-tau217 change at week 48; extension safety, including MRI ARIA, is tracked separately.
Limits/safety: No results are posted. Biomarker change is not proven preservation of memory, everyday function, or delayed dementia. The record does not establish long-term safety. A third-party September 28 date is not evidence of an October launch.
U.S. status / next milestone: Investigational; no new U.S. approval. July 31, 2029 primary/final completion is a registry estimate, not a promised readout.
SAGITTARIUS registers an amyloid vaccine trial before cognitive impairment
Source/event date: First posted September 18, 2026; refreshed September 24. Recovered October 9, rather than a new October start. Evidence: Phase 2 SAGITTARIUS/NCT07827768 registration.
The Institute for Molecular Medicine plans 160 cognitively unimpaired adults with preclinical Alzheimer disease, randomized to AV-1959R amyloid-β vaccine or placebo and followed for 78 weeks. Primary measures include adverse events, MRI ARIA-E/H, other safety assessments, suicidality, and antibody response. Amyloid/other biomarker outcomes are distinct from cognitive prevention.
Limits/safety: Not yet recruiting and no results posted. Generating antibodies or lowering amyloid cannot establish prevention of dementia, healthy years gained, or long-term vaccine safety. This population differs from trials treating symptomatic Alzheimer disease.
U.S. status / next milestone: Investigational vaccine; no new approval. March 1, 2027 estimated start; June 15, 2029 estimated primary/final completion. No guaranteed publication date.
Remaining gaps: Read current topic/state and September5 overlap; all12 saved registry records,32 new-study search matches and recovered SAR448851 live record appraised for scope.; SAR448851 registry access gap closed, historical start July28 retained as baseline. Selected new prevention vaccine registration. No new efficacy inferred from registry refreshes for ClarityAD/PDE4PET/ALN-5288.; All antibody labels/ARIA changes, assay recalls, worldwide prevention cohorts and full blood-test outcomes inventory remain incomplete. Several new biomarker/device records require full appraisal before promotion.
Informal-source coverage: Opened original Oct7–8 r/Alzheimers treatment-or-not thread. It mixes anonymous personal experiences, unsupported universal-treatment claims, and long-delay figures apparently derived from modeling; none establishes new randomized efficacy/safety or individual benefit. Existing Attia/Davidson obicetrapib prevention hypothesis remains unconfirmed. No distinct new development rumor selected.
Focused update — 2026-10-06
Japan registers a study combining digital cognition and blood biomarkers for Alzheimer triage
Source/event date: October 6, 2026 registration. Evidence: Formal observational human study, STRIDE-PAD / UMIN000063185, Japan; no results.
Oita University plans 800 community-dwelling Beppu residents aged 50–89, independent in daily activities and without diagnosed dementia. The study combines community XpressO screening, self-administered MoCA Solo-J in primary care and plasma pTau217/Aβ42. It compares usual primary care, digital assessment alone, blood biomarker alone and a hierarchical combination against specialist assessment including CDR/amyloid PET. Primary measures are accuracy, sensitivity, specificity and predictive values, with Japanese cutoff calibration.
Limits/safety: Observational diagnostic validation does not establish dementia prevention, improved patient outcomes or replacement of specialist diagnosis. False positives, intermediate classifications and downstream testing remain relevant. The record lists preinitiation, although its anticipated September 6, 2026 start has passed; actual start/enrollment are unverified. Industry funders include Theoria Technologies and Fujirebio.
U.S. status / next milestone: Japanese research registration creates no U.S. screening authorization. March 31, 2028 is the listed last follow-up date, not a promised publication date. Confirm actual initiation, then prospective accuracy/workup results.
Coverage: AlzheimertherapybiomarkerbloodtestclinicaltrialOctober2026 after:2026-10-01 before:2026-10-07; site:reddit.com "Alzheimer" "October" "2026" trialobicetrapib; site:clinicaltrials.gov "SAR448851"; "SAR448851" NCT phase2 2026
Remaining gaps: Read full topic/state. Located and opened October 6 UMIN STRIDE-PAD diagnostic-pathway registration; opened original Attia/Davidson public episode page.; SAR448851 program located via official Canada/EMA leads but live CT.gov shell/API unusable; not promoted as new October initiation based on an aggregator's September 28 date.; Full antibody labels/ARIA/assay recalls and prevention registries not refreshed. Original paid Attia transcript unreviewed; no cognitive-prevention benefit from SPINOZA recruitment.
Informal-source coverage: Reopened Attia/Davidson public notes; existing Alzheimer-prevention hypothesis remains unconfirmed despite official SPINOZA recruitment. October 5 Reddit high-dose psilocybin case-report claim surfaced but original page failed; no formal new therapy claim promoted. Full paid transcript/Reddit census incomplete.
Focused update — 2026-10-02
SPINOZA now listed as recruiting
Source/event date: 2026-09-28. Evidence: Trial registry update.
The September 28 ClinicalTrials.gov update lists SPINOZA (NCT07794670) as recruiting, replacing the notebook's not-yet-recruiting snapshot. The planned 400-person, placebo-controlled phase 2 study tests obicetrapib 10 mg daily in preclinical Alzheimer's disease. Its primary outcome is change in plasma p-tau217 at 52 weeks; cognition (PACC5) is secondary. Recruitment is a development milestone, not evidence that obicetrapib prevents dementia. The September 2026 start remains an estimate, so this record does not establish an actual first dose. Primary completion remains September 2028 and final completion May 2029, both registry estimates. No results or Alzheimer's approval were established.
Next milestone: September 2028 primary completion and May 2029 study completion — registry estimates; actual first dose unverified
Coverage: Alzheimer trial results September 29 October 1 2026; Alzheimer blood test September 2026; ClinicalTrials.gov SPINOZA obicetrapib NCT07794670; ALN-5288 NCT07214727; ceperognastat PROSPECT-ALZ JAMA September 22 2026 July publication date; site:reddit.com Alzheimer trial September 2026; Alzheimer prevention obicetrapib informal discussion.
Remaining gaps: Full refresh of antibody safety labels, blood-test regulatory inventory, ALZ101 and matched PrevenTRON registries was not completed. Original Attia/Davidson episode was not reopened; registry now verifies recruiting but not preventive benefit.
Informal-source coverage: Obicetrapib dementia prevention / Attia-Davidson signal; No efficacy confirmation. SPINOZA recruitment is officially registry-listed; do not equate biomarker study with proven prevention. https://www.reddit.com/r/Nutraceuticalscience/comments/1wqjj05/alzheimers_is_no_longer_an_untreatable_disease/; September 26 reposted consensus/personal discussion; no distinct new trial signal.
Next update: SPINOZA primary completion September 2028 estimate; XanaMIA November 2026 topline and RADIANT CTAD November 16–19 remain forecasts/presentations.
Focused update — 2026-09-29
TRONTIER 1 and 2 close recruitment; completion estimates move to February 2028
Source date: 2026-09-25. Evidence: Trial-registry update, no results.
Both pivotal trontinemab trials now list active-not-recruiting status and actual enrollment. NCT07169578/TRONTIER 1: 1,101 participants; NCT07170150/TRONTIER 2: 1,060. Both are randomized placebo-controlled phase 3 studies in early symptomatic Alzheimer disease. Primary outcome is CDR-SB change at week 72. September 25 records estimate primary and study completion February 16, 2028.
Limitations: Exact recruitment-closure date is not supplied. Registry posting is the recorded event date. The new TRONTIER 2 estimate supersedes the notebook’s June 7, 2028 estimate; neither is a promised publication date. This is symptomatic treatment, separate from PrevenTRON prevention.
Safety: No new efficacy or safety results; ARIA, infusion reactions and other harms remain prespecified outcomes.
U.S. status: Trontinemab remains investigational.
Next milestone: February 16, 2028 primary/study completion for both trials — registry estimates; public readout timing unknown.
TRONTIER 1 registry; TRONTIER 2 registry.
Coverage: September 5–29 overlap, prioritizing Sep27–29: symptomatic and prevention discovery; fresh TRONTIER1/2 registry APIs; huperzine controlled-release phase2/3 registry; no duplication of XanaMIA/RADIANT.
Remaining gaps: All antibody labels, diagnostic-clearance/recall databases and prevention registries not comprehensively refreshed. Huperzine program is an older August record, not new September launch. ALZ101/PrevenTRON exact registry matching remains unresolved.
Informal-source coverage: Indexed informal/new-program searches found no new source-grounded clinical-benefit signal; full podcasts and paid transcripts not reviewed. Existing obicetrapib hypothesis not reclassified.
Next update: TRONTIER1/2 completion estimated February 16, 2028; XanaMIA November 2026 topline and RADIANT CTAD November 16–19 remain.
Focused update — 2026-09-27
XanaMIA completes final participant visit; November readout forecast retained
Source date: 2026-09-23. Event date: 2026-09-22. Evidence: Sponsor operational milestone.
Actinogen reported the final XanaMIA participant visit on September 22 in the U.S.; results remain expected in November. The double-blind phase 2b/3 study randomized 247 adults with mild-to-moderate Alzheimer’s disease and elevated pTau181 1:1 to oral Xanamem/emestedastat 10 mg or placebo for 36 weeks, followed by four-week follow-up. Participants were enrolled in Australia and the U.S.; the drug inhibits 11β-HSD1.
Limitations: Visit completion is not a positive efficacy result. The announcement provides no final treatment-effect or safety results; the registry identifier was not independently matched during this run.
Safety: Final comparative safety results pending.
U.S. status: Investigational; sponsor explicitly states no FDA or other global approval outside trials.
Next milestone: November 2026 topline results — sponsor forecast, no exact day.
Actinogen XanaMIA final-visit announcement.
Remlifanserin misses Alzheimer psychosis primary endpoint; phase 3 continues
Source date: 2026-09-24. Event date: 2026-09-24. Evidence: Sponsor phase 2 randomized topline results.
RADIANT’s phase-2 portion missed its primary endpoint despite a nominal secondary signal; Acadia plans continued phase-3 enrollment. At six weeks, SAPS-H+D change with 60 mg was −12.6 versus −10.4 placebo (effect size .26; p=.0603). CGI-S-ADP changed −1.3 versus −.9 (effect size .37; nominal p=.0077). The 30-mg arm showed minimal benefit and is planned for removal from phase 3.
Limitations: Analyses used a prespecified modified population. Sample counts, confidence intervals and complete tables were not disclosed. These outcomes concern hallucinations/delusions, not Alzheimer progression or prevention.
Safety: Sponsor reported similar adverse-event, serious-event and discontinuation rates, no QT signal and no deaths in active arms; quantitative tables and longer follow-up remain needed.
U.S. status: Investigational for Alzheimer psychosis; not an SSRI.
Next milestone: Detailed results at CTAD, November 16–19, 2026, Boston; exact presentation day not specified. Two phase-3 trials continue.
Acadia RADIANT phase-2 release.
Coverage: Primary sponsor developments September 5–27; new XanaMIA milestone and RADIANT results; SPINOZA status; selected diagnostic and prevention searches.
Remaining gaps: Not a complete registry/label refresh across all amyloid antibodies and screening programs. XanaMIA registry matching and detailed endpoints remain unverified; ALZ-101/PrevenTRON new-program leads not fully appraised. Full Acadia conference call, forthcoming CTAD packet and all safety tables unavailable or unreviewed.
Informal-source coverage: Revisited Attia–Davidson episode/public notes and relevant Reddit discussion; no new confirmed cognitive-outcome evidence. Full paid transcript not reviewed.
Next update: XanaMIA topline November 2026 (forecast); RADIANT full data CTAD November 16–19 (scheduled conference, presentation day unknown).
Focused update — 2026-09-22
SPINOZA is formally registered to test obicetrapib in preclinical Alzheimer disease
Source date: 2026-08-31. Event date: 2026-08-31. Evidence: Recovered baseline: phase 2b registry, no efficacy result.
The actual SPINOZA registry closes the prior uncertainty about whether the proposed Alzheimer program was registered. NCT07794670, NewAmsterdam Pharma: planned 400-person randomized placebo-controlled phase 2b study of obicetrapib 10 mg in preclinical Alzheimer disease. Primary endpoint: p-tau217 change at 52 weeks. PACC5 cognition is secondary; APOE eligibility is protocol-defined without full genotype criteria disclosed in the public record.
Limitations: First posted August 31, not a September 22 launch. Still not yet recruiting in that snapshot. A biomarker-primary study cannot by itself establish reduced dementia incidence.
Safety: No trial results or safety outcomes posted.
U.S. status: Not FDA-approved for Alzheimer prevention.
Next milestone: Registry estimates: start September 2026, primary completion September 2028, study completion May 2029. Actual initiation not verified.
SPINOZA original registry; Attia/Davidson September 14 episode notes.
p-tau217 plus APOE refines cognitive-risk estimates in pooled cohorts
Source date: 2026-09-09. Event date: 2026-09-09. Evidence: Peer-reviewed pooled prospective human cohorts; prognostic model/association.
A multi-cohort study connects plasma p-tau217 and APOE with later cognitive impairment, without testing screening-guided prevention. Seven cohorts across Canada, Dominican Republic and the U.S.: 8,582 baseline participants, 4,569 cognitively unimpaired in longitudinal analyses. Per 1-SD higher p-tau217, incident MCI/dementia HR 1.41 (95% CI 1.22–1.64); APOE ε4 carriers 1.76 (1.36–2.26), noncarriers 1.26 (1.12–1.42).
Limitations: Risk association/modeling, not a treatment or test-guided outcome trial. Group-level timing is not an individual countdown. Cohorts include substantial Black and Hispanic representation, but calibration and transfer across ancestry/populations remain relevant.
Safety: No intervention safety assessment; misclassification and interpretation limits matter.
U.S. status: No new screening authorization results from this paper; do not extend symptomatic diagnostic-test indications to healthy-population screening.
Next milestone: Prospective testing of clinical utility and external calibration; no dated follow-up verified.
Xu et al., Lancet Neurology original paper; Primary publication abstract; Investigator explanation.
PrecivityAD2 FDA clearance recovered in baseline audit
Source date: 2026-08-19. Event date: 2026-08-19. Evidence: Recovered baseline: original FDA 510(k) clearance.
FDA cleared PrecivityAD2 on August 19; the September news item is not a new regulatory decision. K253240 combines plasma Aβ42/40 and percentage p-tau217 into APS2. Intended for adults 40+ with cognitive symptoms undergoing Alzheimer/cognitive-decline evaluation, together with clinical assessment.
Limitations: FDA labeling explicitly excludes screening and stand-alone diagnosis. Diagnostic amyloid-pathology assessment does not prove better patient outcomes from screening.
Safety: False positive/negative interpretation risks; avoid extrapolating beyond intended population.
U.S. status: FDA-cleared diagnostic aid; not clearance for asymptomatic population screening.
Next milestone: No new dated milestone verified.
FDA clearance letter and indications, August 19; FDA database decision.
Coverage: Read full topic, baseline/state and September18 gaps; September5–22 treatment, blood-test, human prevention, safety/negative searches. Verified SPINOZA original registry and FDA PrecivityAD2 clearance, appraised p-tau217/APOE original abstract and investigator discussion. Revisited Attia/Davidson original notes. Earlier ALZ101, PrevenTRON and tau-platform entries deduplicated.
Remaining gaps: Exact ALZ101 phase2 and PrevenTRON registry matching remains unresolved. All current anti-amyloid labels/recall-database changes and older lithium/XPro/external-counterpulsation full papers were not comprehensively appraised. SPINOZA registration is verified but actual enrollment/start is not; September estimate is not confirmation. Full p-tau217/APOE paper not accessed; original abstract used. Grifols forthcoming November RWE presentation identified, without new numerical results to appraise.
Informal-source coverage: Rechecked the original September14 Attia/Davidson episode chapter notes; registered-study existence now verified independently, preventive benefit remains a hypothesis. Targeted recent Reddit Alzheimer/biomarker queries mostly personal anecdotes or reposts; no separate new verified efficacy rumor extracted. Full podcast/transcript sweep remains incomplete.
Next update: SPINOZA start estimated September 2026, primary completion September 2028; actual initiation remains unverified. ALZ-101 enrollment forecast year-end 2026 / early 2027.
Focused update — 2026-09-18
ALZ-101 phase 2 enters operational preparation
Source date: 2026-09-10. Evidence: sponsor trial-development announcement.
Alzinova announced operational start-up of its therapeutic Alzheimer vaccine phase 2 study, not first enrollment or dosing. Global randomized placebo-controlled study plans about 120 early-AD participants, ADCOMS change at 52 weeks as primary endpoint and 92-week total follow-up. CRO kick-off completed; regulatory/ethics submissions and site preparations ongoing.
Limitations: Preparation is not recruiting status or efficacy evidence. No matched phase 2 registry ID verified.
Safety: No new safety result in announcement.
U.S. status: Investigational therapeutic vaccine, not approved prevention.
Next milestone: Sponsor forecast: First enrollment around the turn of 2026/2027; no results date announced.
PrevenTRON opens a UK prevention-study site
Source date: 2026-09-05. Evidence: trial-investigator site announcement.
Surrey and Borders NHS announced that its PrevenTRON site opened for asymptomatic people at elevated Alzheimer risk. Phase 3 trontinemab prevention study plans about 1,600 adults aged 55–80 worldwide; blood biomarkers aid enrollment. Source supports UK/Europe site opening and recruitment invitation, not exact first-dosing date.
Limitations: No prevention outcome data. Do not conflate this asymptomatic cohort with symptomatic TRONTIER or approved symptomatic anti-amyloid treatment.
Safety: No new trial safety findings reported; clinical monitoring remains part of investigational treatment.
U.S. status: Trontinemab prevention remains investigational.
Next milestone: No announced readout date: Track first dosing, matching registry and prevention outcomes.
September 5 NHS investigator announcement.
Alzheimer Tau Platform adds combination-treatment research
Source date: 2026-09-08. Evidence: recovered baseline; current trial registry.
The Alzheimer Tau Platform is an existing recruiting phase 2 program studying tau therapies alone or with donanemab. NCT06957418, USC; master-protocol planned enrollment 900, actual start July 6, 2026. Adults 50–80 with late preclinical/early prodromal AD. Launch regimen AADvac1; later Tau2 regimen is unnamed. Randomized masked comparisons include tau therapy alone, combination and donanemab alone; primary outcome tau PET reduction.
Limitations: Master-protocol target is not enrollment for each arm. Biomarker primary outcome is not established cognitive benefit, and no results are posted.
Safety: No new safety data; combination safety remains under study.
U.S. status: Investigational regimen; donanemab approval does not authorize this preventive/combination use.
Next milestone: Registry estimate: Primary/overall completion August 31, 2028; no announced publication date.
Related findings:
- Rapamycin pilot reports brain-perfusion increases in APOE4 carriers: A four-week study reports a cerebral blood-flow signal in cognitively normal APOE4 carriers; it did not test prevention of dementia or longer life.
- Neuro-DORA studies sleep treatment and neurodegeneration biomarkers: New to this notebook, Neuro-DORA is an existing small trial of lemborexant and blood biomarkers, not a newly launched dementia-prevention trial.
Coverage: Read current topic and Sept14 gaps; checked Sept5–18 human evidence and safety/negative searches, original ALZ-101/PrevenTRON announcements and direct AHEAD/TRAILBLAZER/TRONTIER/CELIA/tau-platform/PDE4 registries. No new efficacy result from the established named programs was verified; newly recovered operational/program additions above. This is a focused review, not a complete re-review of every program.
Remaining gaps: Blood-assay recall/clearance databases and newest drug labels not comprehensively re-appraised. Exact PrevenTRON registry/first dosing not matched. ALZ-101 phase2 ID not verified. Older lithium, external-counterpulsation and XPro paper leads remain full-text baseline-appraisal gaps; temporary Sep15 report is not a completed notebook update. PDE4 PET NCT07169630 is recruiting with September 23 estimated start after September 18 update; no validation outcomes. Not promoted to feed.
Informal-source coverage: Original Attia/Davidson September 14 episode notes checked with timestamps; clinical-benefit discussion is not a result. Recent Reddit Alzheimer threads largely anecdotal biomarker testing or reposts. No new independently appraised efficacy rumor.
Next update: No firm immediate readout. Prevention study primary-completion estimates begin November 2027, with several pivotal programs in 2028.
Tracked programs and current evidence
Blood biomarkers (Lumipulse and Elecsys); lecanemab/Leqembi and donanemab/Kisunla; prevention trials AHEAD 3-45 and TRAILBLAZER-ALZ 3; trontinemab/TRONTIER; diranersen/BIIB080/CELIA.
Baseline evidence
2026-09-12 — Initial evidence baseline
Blood tests are advancing diagnosis in people with cognitive concerns, not validated population screening. FDA cleared Fujirebio's Lumipulse pTau217/amyloid-beta ratio in May 2025 for symptomatic adults aged 55 or older; it is not a standalone diagnosis or general screening test. FDA's evaluation used 499 plasma samples from cognitively impaired adults. A Class II recall, posted February 5, 2026, covers specified Lumipulse reagent lots because falsely elevated ratios could produce incorrect positive or indeterminate classifications; this is a lot-specific issue, not withdrawal of every assay. FDA clearance; FDA recall.
Roche's Elecsys pTau217 received FDA clearance August 19, 2026 (announced August 24), for adults 55+ with signs, symptoms or complaints of cognitive decline, used with other clinical information. It provides positive/intermediate/negative assessment of amyloid pathology. FDA-reviewed performance used stored samples from clinical cohorts with amyloid PET as reference; it does not demonstrate that asymptomatic testing prevents dementia. Watch independent prospective validation, effects of renal disease and other confounders, intermediate-result burden, diagnostic workflows and clinical utility. Next update: no reliable dated results milestone identified for these diagnostic programs. FDA decision; FDA-reviewed intended use and study methods.
Approved disease-modifying treatment: Leqembi (lecanemab; pivotal NCT03887455) and Kisunla (donanemab; NCT04437511) are used in early symptomatic, amyloid-confirmed disease. Randomized trials demonstrated slower decline, not cure or established prevention in healthy adults. FDA approved Leqembi's subcutaneous initiation regimen on July 13, 2026, allowing home dosing from the start. That formulation relied on pharmacokinetic/amyloid bridging to IV efficacy, not a separate large clinical-outcome trial. Kisunla is given by monthly IV infusion. Both require attention to ARIA/hemorrhage, APOE-related risk and monitoring burden. Next update: no dependable date identified for the next major safety or long-term clinical-outcome release. FDA Leqembi update; FDA Kisunla evidence.
Prevention is still being tested. Phase 3 TRAILBLAZER-ALZ 3 (donanemab, NCT05026866; approximately 2,996 participants) and AHEAD 3-45 (lecanemab, NCT04468659; approximately 1,400) study biomarker-selected people before dementia. Both are active, not recruiting in checked records. Registry-estimated primary completion: November 2027 and December 21, 2028, respectively; these are not promised publication dates. Clinical progression and cognition matter more than plaque reduction. TRAILBLAZER registry; AHEAD registry.
Trontinemab uses a brain-transport mechanism to deliver an anti-amyloid antibody. Phase Ib/IIa Brainshuttle AD (NCT04639050) supplied amyloid/biomarker and early safety findings; Roche presented extension data July 2026. These do not yet establish superior clinical benefit. Phase 3 TRONTIER 1/2 (NCT07169578/NCT07170150) are underway; TRONTIER 2's registry-estimated completion is June 7, 2028, with no firm readout date verified. Watch cognition/function, ARIA, discontinuations and durability. Roche also announced the PrevenTRON prevention design; enrollment/start timing was not established here. Roche July update; TRONTIER 2.
Diranersen (BIIB080), a tau-lowering antisense therapy, is the leading non-amyloid watch item here. Phase 2 CELIA (NCT05399888) missed its primary dose-response endpoint. Biogen's May/July 2026 conference reports nevertheless describe tau reduction and favorable prespecified cognitive analyses, with the lowest dose showing 26% less CDR-SB decline. These are sponsor-reported Phase 2 findings, not confirmatory efficacy. Biogen plans Phase 3; no reliable start/readout date was verified. Watch full publication, multiplicity, absolute effects, adverse events and actual registration. May primary-endpoint disclosure; July data.
Coverage gap: selective programs only; a full assay comparison and systematic review of all non-amyloid mechanisms remain outside this initial brief. Registry completion estimates may move and must be rechecked.
Rumors and informal signals
September 27 status check: Existing claims remain unconfirmed; no material status change or repeat alert.
- obicetrapib_attia_davidson_2026_09_14_alz_prevention_discussion — unconfirmed: Formal SPINOZA program existence remains independently established, but registry still says not-yet-recruiting with estimated September 2026 start. No new cognitive-prevention benefit established. Public episode material is not a fully appraised paid transcript. Michael Davidson on The Drive; ClinicalTrials.gov NCT07794670.
September 22 follow-up: SPINOZA registration is now independently verified; the earlier prevention-benefit hypothesis remains unconfirmed. Registry entry is not cognitive-outcome evidence. NCT07794670.
October 2 follow-up: The September 28 registry update now lists SPINOZA as recruiting. This confirms recruitment status, not an actual first-dose date or dementia-prevention benefit. The earlier prevention-benefit hypothesis remains unconfirmed; the primary endpoint is a blood biomarker. Current registry.
2026-09-14 — Informal statement / hypothesis — clinical benefit unconfirmed
Michael Davidson discussed obicetrapib Alzheimer biomarker evidence and the need to test clinical prevention benefit on The Drive #407.
Michael Davidson, NewAmsterdam founding CEO, interview with Peter Attia; sponsor connection disclosed. Verified original public chapter notes, not complete paid transcript. No new controlled cognitive outcome or dated prevention-trial promise inferred. Do not treat episode itself as efficacy evidence.
Episode chapter markers: biomarkerDiscussion: Audio 1:17:45 / video 1:29:11; clinicalTranslation: Audio 1:28:00 / video 1:41:33.
Original source. Checked September 18; status remains unconfirmed. Actual prospective prevention registration and clinical endpoints; avoid repeating established lipid data as new.
Dated history
2026-10-02 — Scheduled focused review
1 newly recorded findings or milestones; primary evidence, uncertainty and incomplete coverage are detailed above and in the run record. Full-topic successful-check dates remain unchanged.
2026-09-29: 1 sourced entries, 0 cross-topic links and 0 informal-source checks. Coverage and gaps.
2026-09-27: 2 sourced entries and 0 cross-topic links from a focused scheduled check. Coverage and remaining gaps.
2026-09-22: Focused scheduled research retry; 3 sourced entries and 0 cross-topic links. Coverage and gaps.
September 14, 2026 — focused ad-hoc review
The September 5–14 overlap search checked Biogen releases, Roche program information, and Lilly pipeline material, plus searches for new human trials, negative results and informal discussion. No material new therapeutic finding was verified in this bounded pass. Recent-looking stories often concerned older studies or preclinical work.
Coverage gaps: AHEAD, TRAILBLAZER, TRONTIER and CELIA registries and blood-assay regulator/recall records were not fully rechecked. Lithium/MCI and external-counterpulsation publication leads still need original-paper/date appraisal; older ALZ-101 and XPro1595 papers are baseline leads, not new September results. Indexed Reddit searches did not establish a new specific program rumor; podcasts and interviews were not comprehensively searched. This is a selective review, not an all-clear or a new complete baseline.
Dated findings
The dated baseline entries are preserved under Baseline evidence.
2026-09-18 — Scheduled focused review
Read current topic and Sept14 gaps; checked Sept5–18 human evidence and safety/negative searches, original ALZ-101/PrevenTRON announcements and direct AHEAD/TRAILBLAZER/TRONTIER/CELIA/tau-platform/PDE4 registries. No new efficacy result from the established named programs was verified; newly recovered operational/program additions above. Original event dates, safety and limitations are retained in the September 18 update above. The complete-topic successful-check date was not advanced because the listed gaps remain. Run record.